Amgen Inc.
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell counā¦ read more
Healthcare
Drug ManufacturersāGeneral
42 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$296.47
Price+2.13%
$6.18
1Y
Price
Market Cap
$159.608b
Large
Price/Earnings 3y Avg5y Avg
24.3x
Premium
Premium
Financials Overview
Key metrics over the past few years+39.5%
EBITDA Margin+15.6%
Net Profit Margin+20.9%
Free Cash Flow MarginRevenue
$34.905b
+4.4%
1y CAGR+10.0%
3y CAGR+7.9%
5y CAGREarnings
$6.619b
+61.8%
1y CAGR+8.4%
3y CAGR+9.1%
5y CAGREPS
$12.23
+61.8%
1y CAGR+8.5%
3y CAGR+10.8%
5y CAGRBook Value
$7.428b
$87.897b
Assets$80.469b
Liabilities$56.204b
DebtDebt to Assets
63.9%
3.5x
Debt to EBITDAFree Cash Flow
$10.605b
+2.0%
1y CAGR+9.0%
3y CAGR+8.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company